Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort

Ohad Atia, Renz C.W. Klomberg, Lissy de Ridder*, Polychronis Kemos, Frank M. Ruemmele, Ben Kang, Sujin Choi, Byung Ho Choe, Youra Kang, Dror S. Shouval, Gili Focht, Oren Ledder, Raffi Lev-Tzion, Natalie Carmon, Tal David Berger, Dan Turner, Nicholas M. Croft, Esther Orlanski-Meyer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Several studies have proposed models to predict disease outcomes in paediatric ulcerative colitis (UC), notably PROTECT, Schechter and PIBD-ahead, but none has been validated by external cohorts. Aim: To explore these models in a prospective multicentre inception cohort. Methods: Children newly diagnosed with UC in 17 centres were followed at disease onset and 3 and 12 months thereafter, as well as at last visit. Outcomes included steroid-free remission (SFR) and acute severe colitis (ASC). Results: Of the 223 included children, 74 (34%), 97 (43%) and 52 (23%) presented with mild, moderate and severe disease, respectively. SFR rate was 35% at 3 months and 47% at 12 months (62% of those with mild disease at diagnosis vs. 41% in moderate–severe disease; p = 0.01). Thirty-six (16%) children developed ASC during the first month after diagnosis, and 53 (24%) during the first year. The AUC of the PROTECT model for predicting SFR at 3 and 12 months was 0.78 [95% CI 0.65–0.92] and 0.57 [95% CI 0.47–0.66], respectively. The sensitivity/specificity/PPV/NPV of Schechter's criteria to predict sustained SFR at 12 months was 50%/60%/35%/74%. ASC was predicted only by the PUCAI score at diagnosis and at 3 months. Conclusions: The PROTECT model had a good predictive utility for SFR at 3 months, but not at 12 months. The other predictive models did not achieve sufficient accuracy, which was far from that reported in the original studies. This highlights the necessity for external validation of any prediction model prior to its implementation into clinical practice.

Original languageAmerican English
Pages (from-to)182-190
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Issue number2
StatePublished - Jul 2023

Bibliographical note

Funding Information:
OA, RK, OK, FMR, SC, BHC, YK, OL, RLT, NC and TDB—None. LdR—Collaborations (such as involvement in industry‐sponsored studies, investigator‐initiated studies, consultancy) with AbbVie, Lilly, Takeda, Janssen and Pfizer. BK—In the last 3 years received speaker fee, consultation fee or research grant from Celltrion, Janssen, Eisai, AbbVie, Takeda, Yuhan, Yungjin and JW Pharmaceutical. DSS—Research grant from Takeda; consulting and lecturing fees from Jansen and AbbVie. GF—Received consultation fees from AbbVie and Lilly in the last 3 years. DT—In the last 3 years received consultation fee(s), research grant(s), royalties or honoraria from Janssen, Pfizer, Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, Thermo Fisher, BMS and SorrisoPharma. NMC—AbbVie, Shire, Takeda, Lilly and Pfizer for lectures and research fees (trials) all paid to NMC's employer. EOM—Lecture fees were received in the last 3 years from Takeda and Abbott.

Publisher Copyright:
© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.


Dive into the research topics of 'Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort'. Together they form a unique fingerprint.

Cite this